Biogen Inc. (NASDAQ:BIIB).
Swedbank reports that it decreased its position in Biogen Inc. stock by 48,930 shares in its quarterly SEC filing. Its investment was worth $156,961,000 a decrease of 8.5% according to the filing.
The following firms have also recently changed their position in BIIB. Gateway Investment Advisers LLC grew its stake by buying 15,260 shares an increase of 10.5% in the quarter. Gateway Investment Advisers LLC now controls 160,003 shares valued at $43,418,000. The value of the position overall is up by 9.7%. As of quarter end Hills Bank & Trust Co had acquired 197 shares growing its position 5.0%. The value of the company’s investment in Biogen Inc. increased from $1,067,000 to $1,112,000 a change of $45,000 quarter to quarter.
As of the end of the quarter Clinton Group Inc had sold a total of 16,382 shares trimming its holdings by 82.3%. The value of the total investment in Biogen Inc. went from $5,647,000 to $965,000 a change of 82.9% quarter over quarter.
On July 11 Morgan Stanley kept the company rating at “Equal-Weight” but moved down the price target to $301.00 from $368.00. On June 19 the company was upgraded from “Neutral” to “Buy” in a report issued by UBS.
On November 8 analysts at Mizuho starting coverage on BIIB with an initial rating of “Overweight”. On November 7 the company was rated “Outperform” by Leerink Swann which is up from the previous “Market Perform” rating.
On November 7 the stock rating was upgraded to “Overweight” from “” in a report from PiperJaffray. On September 6, 2016 the stock rating was set at “Hold” in a report from Jefferies which was a cut from the previous “Buy” rating.
The company is up since yesterday’s close of $271.76. Shares are trading at $273.76 which is just over $259.24, the 50 day moving average and which is a tad under the 200 day moving average of $274.78. The 50 day moving average was up $14.97 and the 200 day average moved down $-0.58.
The company currently has a P/E ratio of 17.1744 and the market cap is 58.16B. In the last earnings report the EPS was $15.97 and is projected to be $20.48 for the current year with 212,115,000 shares outstanding. Next quarter’s EPS is forecasted at $5.34 with next year’s EPS projected to be $22.53.
Short traders are feeling a little more bearish on Biogen Inc. considering the change in short interest. The firm had a rise in short interest of 23.23% as of May 31, 2017 from the last reporting period. Short interest grew 563,405 over that period. Days to cover increased 0.2 to 1.9 and the percentage of shorted shares was 0.01% on May 31.